(Circulation. 2006;113:e382-e385.)
© 2006 American Heart Association, Inc.
Clinician Update |
From the Department of Medicine (E.J.A.), Massachusetts General Hospital, Boston, Mass, and the TIMI Study Group (D.A.M., M.S.S.), Cardiovascular Division, Brigham and Womens Hospital, Boston, Mass.
Correspondence to Marc S. Sabatine, MD, MPH, Cardiovascular Division, Brigham and Womens Hospital, 75 Francis St, Boston, MA 02115. E-mail msabatine@partners.org
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
| Introduction |
|---|
Metalloproteinases
MMPs are zinc-dependent endoproteases with collagenase and/or gelatinase activity (Table). Degradation of collagen fibrils compromises plaque stability and the integrity of the endothelial basement membrane, predisposing advanced atheromas to rupture.1
|
MMP-1, -2, and -9
MMP-1, a collagenase expressed in the interstitium, is quickly upregulated in animal models of coronary ischemia/reperfusion. MMP-2 is a gelatinase capable of degrading type IV collagen, the major collagen of the subendothelial basement membrane. MMP-9 is a gelatinase widely implicated in ventricular remodeling and the development of heart failure.2
MMPs are highly expressed in atherosclerotic plaques, with selective enrichment at the shoulder regions.3 Patients with ACS have increased plasma levels of MMP-1, -2, and -9.4 The time course of elevation is highly variable: some groups have found that MMP-1, -2, and -9 levels are not elevated at presentation but that they increase during the subsequent 7 to 14 days.5 Other groups have reported no significant elevation in MMP-2 but a rapid rise and fall of MMP-9 within the first week after ACS.
Few data exist on the association, if any, between MMP levels during ACS and cardiovascular outcomes. In a study of 24 patients with ACS, elevations in MMP-1 at 7 and 14 days after ACS were negatively correlated with left ventricular ejection fraction.6 The slow elevation of MMP levels after ACS and the lack
Related Article:
Circulation 2006 113: 1155.
This article has been cited by other articles:
![]() |
F. Cambronero, F. Marin, V. Roldan, D. Hernandez-Romero, M. Valdes, and G. Y.H. Lip Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis Eur. Heart J., January 9, 2009; (2009) ehn538v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ardigo, T. L. Assimes, S. P. Fortmann, A. S. Go, M. Hlatky, E. Hytopoulos, C. Iribarren, P. S. Tsao, R. Tabibiazar, T. Quertermous, et al. Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease Physiol Genomics, November 14, 2007; 31(3): 402 - 409. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Giugliano and E. Braunwald The Year in Non-ST-Segment Elevation Acute Coronary Syndromes J. Am. Coll. Cardiol., July 18, 2006; 48(2): 386 - 395. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |